1. Home
  2. FGI vs ONCO Comparison

FGI vs ONCO Comparison

Compare FGI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FGI Industries Ltd.

FGI

FGI Industries Ltd.

HOLD

Current Price

$5.67

Market Cap

7.5M

Sector

Industrials

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$1.14

Market Cap

1.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGI
ONCO
Founded
1987
2018
Country
United States
United States
Employees
420
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
1.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FGI
ONCO
Price
$5.67
$1.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
52.6K
4.1M
Earning Date
04-09-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.80
EPS
N/A
N/A
Revenue
N/A
$815,371.00
Revenue This Year
$6.38
N/A
Revenue Next Year
$6.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.07
52 Week High
$12.62
$7.65

Technical Indicators

Market Signals
Indicator
FGI
ONCO
Relative Strength Index (RSI) 49.02 60.96
Support Level $5.34 $0.49
Resistance Level $6.32 $1.44
Average True Range (ATR) 0.61 0.09
MACD 0.01 0.09
Stochastic Oscillator 67.16 77.02

Price Performance

Historical Comparison
FGI
ONCO

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: